1. State the objective and constraints.
Write a short decision brief before approaching buyers, licensees, or funders. Is the goal to produce near-term cash, protect a market position, support a partnership, reduce portfolio expense, or build a longer-term licensing program? Rank the goals if they conflict.
Document the constraints: management time, available capital, remaining patent life, sensitive customer relationships, existing agreements, and the owner’s tolerance for a public dispute. Include the consequences of doing nothing. Maintaining a portfolio for strategic use can be a deliberate choice, but its costs and purpose should be visible.
A route that looks attractive in isolation may not fit the business. For example, a seller may prefer a more certain payment to a larger contingent return, while a product company may prioritize continued rights to use its technology.
2. Compare the routes on the same terms.
An assignment transfers an ownership interest. A license grants rights within an agreed scope, which can be limited by field, territory, or time. The contract’s substance matters more than its label. USPTO assignment and licensing guidance.
| Route | When to examine it | Questions to resolve |
|---|---|---|
| License | You want to grant defined rights while retaining an ownership interest. | Who needs the rights? What remains reserved? How will payment, reporting, compliance, and enforcement work? |
| Sell | You are willing to transfer specified ownership rights for agreed consideration. | What assets and associated rights transfer? Is a license back needed? Which obligations survive closing? |
| Enforce | Evidence suggests unauthorized use and the business can evaluate a dispute. | Are title, claims, evidence, remedies, cost, and litigation risk sufficiently understood? |
| Hold or narrow | The evidence is incomplete or another objective currently matters more. | What work would change the decision? Which costs and deadlines continue while waiting? |
These routes can interact. A sale may reserve a license; a licensing discussion may resolve a dispute. Evaluate the proposed terms together rather than treating a transaction category as a complete strategy.
3. Test the commercial thesis.
For each priority asset, connect specific claims to a commercial use and identify the evidence supporting that connection. A large market, a recognizable company, or a patent citation does not establish that a particular product practices the claim.
Ask who would rationally pay for the proposed rights and why. Separate a prospective buyer’s strategic interest from an accused user’s potential exposure. List assumptions about product adoption, available alternatives, timing, and the difficulty of obtaining technical evidence. Test the assumptions that would most change the recommendation.
Confirm ownership, remaining term, prior licenses, and restrictions before using the asset in an outreach strategy. The portfolio diligence checklist provides a practical document starting point. A missing agreement can matter more than an optimistic revenue projection.
4. Model net outcomes and downside.
Compare expected receipts with transaction expense, legal and expert work, ongoing administration, funding terms, taxes, and the owner’s retained obligations. Model timing as well as totals. A payment delayed by several years is economically different from cash at closing.
Use a range of assumptions rather than a single headline valuation. Identify what happens if negotiations stop, technical analysis weakens the thesis, litigation costs increase, or proceeds arrive later than expected. Keep gross recoveries separate from distributions to the patent owner.
In litigation, a damages award depends on the claim and evidence; a statutory remedy is not a promised return. Section 284 addresses compensation for infringement, while injunctions under section 283 depend on equitable principles. 35 U.S.C. § 284; 35 U.S.C. § 283.
Funding or insurance, if available and suitable, should be assessed through its actual terms. Ask who controls settlement decisions, what expenses are covered, how proceeds are allocated, and what risk remains with the owner.
5. Choose the next investigation.
A useful decision meeting ends with a defined next step, not simply “explore monetization.” Set an information threshold and a budget for reaching it. That might be a title review, a focused claim analysis, a small set of commercial interviews, or negotiation of a particular transaction.
The boxes are a working aid and are not submitted. Keep the completed analysis with the decision record so the next discussion can focus on changed evidence rather than repeat the original assumptions.